PAM
SEEL

Panagora Asset Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Panagora Asset Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26
Closed -$237K – 1740
2021
Q3 		$237K Hold
26
– – ﹤0.01% 1599
2021
Q2 		$259K Buy
+26
New +$427K ﹤0.01% 1575
2020
Q3 		– Hold
0
– -$1K – 2773
2020
Q2 		– Hold
0
– – – 2527
2020
Q1 		– Hold
0
– – – 2459
2019
Q4 		– Hold
0
– – – 2367
2019
Q3 		– Hold
0
– -$3K – 2663
2019
Q2 		– Sell
-1
Closed -$10.5K – 2517
2019
Q1 		$18K Buy
+1
New +$16.2K ﹤0.01% 2286

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Panagora Asset Management's SEEL Position: Q4 2021 in Review

Panagora Asset Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2021, closing a stake of 26 shares — an estimated $237K sold.

Panagora Asset Management first reported a position in SEEL in Q1 2019 and held it in 3 quarters. The position peaked at $259K in Q2 2021. 82 funds tracked by Wall St. Rank hold SEEL as of Q4 2021.

  • Panagora Asset Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Panagora Asset Management sold 26 Seelos Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $237K.
  • Panagora Asset Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Panagora Asset Management's Seelos Therapeutics, Inc. Common Stock position peaked at $259K in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Panagora Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.